Sort
25,944 grants matching “neurodegeneration”
PREVENTABLE Frailty Ancillary Study
$1,253,145Ariela R Orkaby · Boston Va Research Institute, Inc. · R01 · FY2025 · AG
Interrogation of a human microglia phenotype associated with Alzheimer's disease
$1,252,831Marta Olah · Columbia University Health Sciences · RF1 · FY2021 · AG
CNS DEGENERATION CAUSED BY NOVEL PATHOGENS
$1,252,039University Of California San Francisco · P50 · FY2000 · NS
Neuroimmune responses and therapeutics of alpha-synucleinopathies of the aging population
$1,250,974Eliezer Masliah · National Institute On Aging · ZIA · FY2018 · AG
DNA repair dysfunction in neurodegeneration and Alzheimer's Disease
$1,250,969Vilhelm A Bohr · National Institute On Aging · ZIA · FY2018 · AG
Investigation of the intracellular and extracellular mechanisms underlying the process of aging
$1,250,120Yie Liu · National Institute On Aging · ZIA · FY2025 · AG
Lead Optimization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease
$1,250,000Milton L Greenberg · Vivreon Biosciences, Llc · R44 · FY2019 · AG
Lead Optimization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease
$1,249,999Milton L Greenberg · Vivreon Biosciences, Llc · R44 · FY2020 · AG
Novel platform for research brain banking and characterization using integrated traditional and quantitative analyses to promote precision neuropathology of Alzheimer's disease
$1,249,822Christopher D Keene · Allen Institute · U19 · FY2020 · AG
Einstein Aging Study
$1,249,743Richard B. Lipton · Albert Einstein College Of Medicine, Inc · P01 · FY2015 · AG
Project 1 - Cognitive Function and Dementia
$1,249,672Lisa F Berkman · Harvard University D/B/A Harvard School Of Public Health · P01 · FY2024 · AG
Development of Nav1.1 Enhancers to Treat Alzheimer's Disease
$1,249,502Michael Pleiss · Cure Network Dolby Acceleration Partners Llc · R44 · FY2023 · AG
Development of Nav1.1 Enhancers to Treat Alzheimer's Disease
$1,249,502Michael Pleiss · Cure Network Dolby Acceleration Partners Llc · R44 · FY2022 · AG
SBIR Phase II: High-throughput De-novo Peptide Sequencing with Metasurface Optics
$1,249,115Jack Hu · Pumpkinseed Technologies Inc · · FY2025 · TIP
Novel platform for research brain banking and characterization using integrated traditional and quantitative analyses to promote precision neuropathology of Alzheimer's disease
$1,247,582Christopher D Keene · Allen Institute · U19 · FY2021 · AG
Amadorins for Ameliorating Alzheimer's Disease and Related Dementias (ADRD)
$1,246,076Raja G Khalifah · Praetego, Inc. · R44 · FY2023 · AG
Mitochondrial Proteins in Parkinson's Disease
$1,245,675J Timothy Greenamyre · University Of Pittsburgh At Pittsburgh · P01 · FY2009 · NS
1Florida Alzheimer's Disease Research Center Clinical Core
$1,244,913Ranjan Duara · University Of Florida · P30 · FY2020 · AG
Identifying genes and Pathways that impact Tau Toxicity in FTD
$1,244,334Leonard Petrucelli · Mayo Clinic Jacksonville · U54 · FY2016 · NS
A non-pharmacological multi-modal therapy to improve sleep and cognition and reduce mild cognitive impairment risk
$1,243,520Daniel Gartenberg · Proactive Life, Inc. · R44 · FY2020 · AG
Genomic regulation of immune response in neurodegeneration in mice
$1,243,075Han-Yu Shih · National Eye Institute · ZIA · FY2020 · EY
ALZHEIMER'S DISEASE CORE CENTER
$1,242,135William R Markesbery · University Of Kentucky · P30 · FY2008 · AG
NEURONAL &VASCULAR PATHOBIOLOGY IN ALZHEIMER'S DISEASE
$1,241,767Nathan S. Kline Institute For Psych Res · P01 · FY2003 · AG
Physiologic and Pathologic Coupling in the Neurovascular Unit
$1,240,715Eng H. Lo · Massachusetts General Hospital · P01 · FY2009 · NS
TAU AND NEURODEGENERATION
$1,240,362Mayo Clinic Coll Of Medicine, Rochester · P01 · FY2001 · AG